The company will rely more on distribution partners in Europe for its Unyvero product line while continuing highly targeted commercialization efforts in the US.
Roche said the layoffs at its Madison, Wisconsin site will start Dec. 31 and continue through June 30, 2020.
Cooper took a $24.4 million impairment charge in the second quarter on the intangible assets it acquired in 2016 from carrier screening firm Recombine.
The company entered a securities purchase agreement through which it has raised gross proceeds of $650,000 and paid down a portion of the company's debt.
The company acquired GnuBio, which was developing a droplet-based sequencing platform, in 2014 for $39.7 million in cash and $10 million in contingent payments.
The restructuring and job cuts are expected to save the firm more than $70 million annually.
Qiagen's revenues grew 6 percent at constant exchange rates to $349.0 million, besting the average Wall Street estimate of $346.6 million.
The company said that it is extending the maturity of certain obligations under the terms of the acquisition deal until March 2019.
After a 54 percent quarter over quarter rise in sales of the test, Rosetta's CEO said that the realigned strategy will take the firm to profit more quickly.
As part of the deal with an institutional investor, Interpace's royalty and milestone obligations will also be terminated.
An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.
An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.
In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.
Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.